At 8.0% CAGR, the Middle East & Africa Molecular Diagnostics Market is Projected to be Worth US$ 1,532.25 million by 2030, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa molecular diagnostics market was valued at US$ 825.09 million in 2022 and is expected to reach US$ 1,532.25 million by 2030, registering a CAGR of 8.0% from 2022 to 2030. Development of new products and increase in demand for point-of-care testing and surging prevalence of associated diseases are the critical factors attributed to the Middle East & Africa molecular diagnostics market expansion.                     

Point-of-care testing is a branch of medicine with a rapidly evolving analytical scope and clinical application. Point-of-care testing solution providers offer products for various evaluations, ranging from blood glucose measurement to viscoelastic coagulation assays. Eliminating the time of transportation and preparation of clinical samples, these tests enable professionals to make clinical decisions about additional testing or therapy in less time. This emerging healthcare solution is being aggressively adopted by patients and healthcare service providers. Point-of-care assays are extensively used in therapeutics, diagnostics, and patient monitoring applications, among others. Moreover, point-of-care products and services help healthcare providers in meeting patients’ demand for at-home medical care. These products and services proved specifically helpful during the COVID-19 pandemic by allowing patients to take tests from their homes instead of traveling to diagnostic or treatment facilities, thereby lowering the risk of infection. Thus, the rising demand for point-of-care testing benefits the molecular diagnostics market.

On the contrary, limitations associated with molecular testing hurdles the growth of Middle East & Africa molecular diagnostics market.

Based on disease area, the Middle East & Africa molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment held 41.7% share of Middle East & Africa molecular diagnostics market in 2022, amassing US$ 344.16 million. It is projected to garner US$ 648.14 million by 2030 to expand at 8.2% CAGR during 2022–2030.

Based on technology, the Middle East & Africa molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment held 47.3% share of Middle East & Africa molecular diagnostics market in 2022, amassing US$ 389.87 million. It is projected to garner US$ 746.17 million by 2030 to expand at 8.5% CAGR during 2022–2030. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the Middle East & Africa molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment held 64.2% share of Middle East & Africa molecular diagnostics market in 2022, amassing US$ 529.58 million. It is projected to garner US$ 1,017.85 million by 2030 to expand at 8.5% CAGR during 2022–2030.

Based on end users, the Middle East & Africa molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held 39.6% share of Middle East & Africa molecular diagnostics market in 2022, amassing US$ 327.11 million. It is projected to garner US$ 624.03 million by 2030 to expand at 8.4% CAGR during 2022–2030. 

Based on country, the Middle East & Africa molecular diagnostics market has been categorized into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 46.3% share of Middle East & Africa molecular diagnostics market in 2022. It was assessed at US$ 382.12 million in 2022 and is likely to hit US$ 699.67 million by 2030, exhibiting a CAGR of 7.9% during 2022–2030.      

Key players operating in the Middle East & Africa molecular diagnostics market are Abbott Laboratories, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd, Illumina Inc, Novartis AG, Qiagen NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.   

• In July 2023, Thermo Fisher launched new software for molecular diagnostics labs. This software helps in streamlining routine diagnostics testing for standardization and rapid time-to-results. It can enhance the potential of a lab to dynamically respond to quickly changing testing environments by connecting workflow steps within a single interface.  
• In Nov 2021, Thermo Fisher Scientific Inc., the world leader in serving science, has innovative proteomics solutions and a series of co-marketing agreements with industry experts, advancing the throughput, comprehensiveness, and quality of proteomics workflows for applications such as single-cell studies and translational research.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com